Literature DB >> 2653415

Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials.

S Daya1.   

Abstract

Progesterone appears to be necessary to support an early pregnancy, and it has been used for this purpose for several decades. Its potential role in women with recurrent miscarriage due to luteal phase deficiency has been suggested, but its efficacy has not yet been demonstrated. Three controlled trials of progesterone treatment in women with recurrent miscarriage have shown small, but not statistically significant, increases in the rates of pregnancies that continue beyond 20 weeks in the treated groups. None of these studies had sufficient statistical power to detect a clinically significant improvement in outcome but pooling the results of these studies using the principles of meta-analysis has allowed an overall effect of treatment to be calculated. The resulting odds ratio for pregnancies reaching at least 20 weeks gestation was 3.09 (95% CI 1.28 to 7.42) which indicates that there is evidence to support the suggestion that progesterone given in early pregnancy is useful in women with recurrent miscarriage. Although, before progesterone is used in this way its efficacy in women with recurrent miscarriage due to luteal phase deficiency must be assessed in prospective double-blind randomized controlled trials mounted in the light of the results of this meta-analysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653415     DOI: 10.1111/j.1471-0528.1989.tb02386.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  9 in total

Review 1.  The management of preterm labour.

Authors:  Jayanta Chatterjee; Joanna Gullam; Manu Vatish; Steve Thornton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

Review 2.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 3.  Progesterone and the luteal phase: a requisite to reproduction.

Authors:  Tolga B Mesen; Steven L Young
Journal:  Obstet Gynecol Clin North Am       Date:  2015-01-05       Impact factor: 2.844

Review 4.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

5.  Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques.

Authors:  Ravichandran Nadarajah; Hemashree Rajesh; Ker Yi Wong; Fazlin Faisal; Su Ling Yu
Journal:  Singapore Med J       Date:  2016-04-19       Impact factor: 1.858

6.  Lipopolysaccharide-induced murine embryonic resorption involves changes in endocannabinoid profiling and alters progesterone secretion and inflammatory response by a CB1-mediated fashion.

Authors:  Manuel L Wolfson; Fernando Correa; Emma Leishman; Claudia Vercelli; Cora Cymeryng; Julieta Blanco; Heather B Bradshaw; Ana María Franchi
Journal:  Mol Cell Endocrinol       Date:  2015-05-06       Impact factor: 4.102

Review 7.  Evidence-based management of recurrent miscarriages.

Authors:  Yadava B Jeve; William Davies
Journal:  J Hum Reprod Sci       Date:  2014-07

8.  Candidate SNP markers of reproductive potential are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters.

Authors:  Irina V Chadaeva; Petr M Ponomarenko; Dmitry A Rasskazov; Ekaterina B Sharypova; Elena V Kashina; Dmitry A Zhechev; Irina A Drachkova; Olga V Arkova; Ludmila K Savinkova; Mikhail P Ponomarenko; Nikolay A Kolchanov; Ludmila V Osadchuk; Alexandr V Osadchuk
Journal:  BMC Genomics       Date:  2018-02-09       Impact factor: 3.969

9.  Progesterone supplementation in women with otherwise unexplained recurrent miscarriages.

Authors:  Munawar Hussain; Samawal El-Hakim; David J Cahill
Journal:  J Hum Reprod Sci       Date:  2012-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.